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ABSTRACT
Amyloidosis is an uncommon disorder characterized by extracellular deposition of abnormal 
proteins. Breast involvement has rarely been reported and can clinically be misdiagnosed as breast 
cancer. A 60-year-old woman presented with a 3-mm diameter mass in the right breast close to 
a silicon implant positioned 20 years before. A core biopsy, performed to rule out breast cancer, 
showed amyloid deposit. Further exams confirmed a systemic amyloid light chain amyloidosis. 
After few months the mass increased causing breast volume and shape distortion. Since breast 
cancer may be the cause of amyloid deposits or be hidden by it, the patient underwent a bilateral 
skin sparing mastectomy and expander and fat grafting breast reconstruction. The resection 
specimens showed amyloid deposits only, no evidence of cancer. At 2 years follow-up, no breast 
amyloidosis recurrence was shown. Breast amyloidosis is rare but can occur in a plastic surgeon’s 
practice. It is mandatory to rule out a comitant breast cancer or systemic amyloidosis.
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INTRODUCTION
Amyloidosis is an uncommon disorder characterized by 
extracellular deposition of amorphous and insoluble 
proteins in an abnormal fibrillary configuration. Despite 
the various morphologic manifestations in tissue, 
staining for amyloid protein with Congo red reveals a 
characteristic apple-green birefringence under polarized 
light. The most common types of amyloidosis are amyloid 
light chain (AL) and amyloid A (AA). AL, caused by 
immunoglobulin light-chains [amyloid heavy chain (AH) is 
more rare and caused by heavy chains], is secondary to 
plasma cell dyscrasia (clonal plasma cell disorder 
secreting fibril-forming monoclonal immunoglobulin), 
while AA is reactive amyloidosis associated with chronic 
inflammatory disease (rheumatoid arthritis, Reiter 
syndrome, etc.).[1] The precise aetiology and pathogenesis 
of amyloidosis are unknown.
AL amyloidosis can be systemic, affect more than one 
organ or tissue (commonly involving heart, gastrointestinal 
tract and tongue), or less commonly localized, affecting 
individual organs.
Breast involvement by amyloidosis has rarely been 
reported in the literature, first by Fernandez and 
Hernandez[2] in 1973. Breast amyloidosis can be part of a 
systemic amyloidosis disease or it may be limited to the 
breast and therefore be cause of misdiagnosis.
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In the vast majority of patients, breast amyloidosis is part 
of a systemic AL type disease (usually kappa light chain 
proteins). It can be associated with malignancies of the 
breast including invasive ductal or lobular carcinoma but 
mainly it is associated with hematologic malignancies.
Moreover, breast cancer may sometimes be the cause of 
amyloid, the so-called amyloid tumour of the breast but 
it is rare.[3] 
The typical clinical presentation of breast amyloidosis is 
a painless, solitary or multiple breast mass. Mammogram 
shows a mass of focal or diffuse density with or without 
calcification.
CASE REPORT
A 60-year-old woman presented in 2011 with a non-
palpable 3-mm diameter mass visualized at ultrasound in 
the right breast close to a silicone implant imaging 
[Figure 1].
She had a bilateral breast augmentation with silicone gel 
implants 30 years before.
Comorbidities, on regular treatment, were hyperthyroidism, 
hypertension and heart failure.
Although the first mammogram did not suspect a 
malignant lesion, but only showed heterogeneously 
dense breast, the clinical suspicion was breast cancer or 
silicon leakage.
Magnetic resonance imaging (MRI) did not show implant 
rupture. A fine needle aspiration cytology was performed, 
which was negative for malignancy, and reported a non-
specific inflammatory reaction only.
At 2 years follow-up, the mass size increased to 3 cm. An 
ultrasound guided core needle biopsy was performed 
and the histological examination showed amyloid 
deposits but no evidence of cancer. Amyloid deposits 
appeared as eosinophilic amorphous material with 
lymphocytes, plasma cells and multinucleated giant cells 
and showed characteristic staining with Congo Red 
(under fluorescence light and laser microdissection). 
Amyloid typing, performed by immunohistochemistry 
(immunoperoxidase staining on paraffin sections of the 
breast using antibodies), showed immunoglobulin-
associated mixed light chains (kappa and lambda) and 
heavy chains.
Our first hypothesis was that amyloid deposits could be 
related to a local inflammation (silicon leakage) or could 
be due to a breast cancer or could be part of a systemic 
amyloidosis. Further investigations confirmed a systemic 
AL amyloidosis.
In a few months, the breast mass increased in volume and 
new nodules appeared causing breast volume and shape 
distortion. At ultrasound several masses were found in 
both breasts.
The MRI showed global replacement of normal parenchyma 
with mixed hyper and hypo echogenic masses that formed 
a conglomerate coalescent mass in the superior right 
breast close to the implant [Figure 2]. In accordance with 
the patient, a bilateral skin sparing mastectomy and 
implant removal was performed [Figure 3].
Figure 1: Right breast ultrasound imaging
Figure 2: Magnetic resonance imaging of the breast: demonstrating a 
conglomerate coalescent mass in the superior right breast upon the 
implant Figure 3: Pre operative pictures and surgical plan
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The resection specimens of both breasts showed nodular 
amyloid deposits only, with no evidence of cancer or 
calcifications [Figure 4]. Multinucleated giant cells were 
present within and adjacent to the amyloid deposits. 
Focal aggregates of lymphocytes (B and T) and plasma 
cells were also found.
The patient opted for a bilateral reconstruction with fat 
grafting. Two 470 mL expanders were positioned under 
the pectoralis major muscle at the time of mastectomy 
and gradually inflated on an outpatient basis.
In three consecutive surgeries the expanders were 
gradually deflated and that volume replaced by fat grafts 
according to the Coleman technique.
At two years of follow-up, MRI did not show any breast 
amyloidosis recurrence [Figure 5].
The patient is satisfied with the reconstruction. No 
significant fat resorption was shown [Figure 6].
She is under follow-up for systemic amyloidosis and did 
not show involvement of other organs until now.
DISCUSSION
Röcken et al.[4] and Charlot et al.[5] reported that breast 
amyloidosis is associated with invasive cancer (ductal or 
lobular carcinoma or lymphoma). Other studies[6,7] 
showed that comitant malignancies may be absent, as 
happened in our case.
Although breast amyloidosis is most commonly AL type, 
our patient had a systemic amyloidosis of the AH/AL type. 
Breast amyloidosis doesn’t have specific clinical or 
radiographic features. In the majority of cases it is not 
suspected clinically; instead, breast biopsies are usually 
done to rule out malignancy.
The pathogenesis of localized breast amyloidosis in the 
absence of a concomitant breast lymphoma or plasma 
cell dyscrasia is unknown, probably originating from local 
plasma cells secreting immunoglobulins. Plasma cell 
proliferation by itself is probably not sufficient to trigger 
amyloid deposition, and undetermined factors are 
needed for amyloid deposition.[5] 
Prosthetic breast implantation is one of the world’s most 
popular aesthetic surgical operations.
The amyloid fibril proteins deposited in the breast of our 
patient were not of epithelial origin. Nevertheless, one 
may suggest a reaction link between leakage of silicon 
and deposition of amyloid deposits. The role of silicone 
gel in relation to connective tissue disease and 
amyloidosis has not been proved by current serologic, 
immunologic, or epidemiologic test. We found 
multinucleated giant cells within or adjacent to amyloid 
deposits; multinucleated giant cells may represent a Figure 4: Resection specimens of the breasts
Figure 5: Magnetic resonance imaging of the breasts at 2 years of 
follow-up
Figure 6: Patient appearance at 2 years of follow-up
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tissue response but also they have been described in 
amyloidosis of the breast and they might be involved in 
the resorption of amyloid deposits by synthesized 
proteases.[8]
In conclusion, breast amyloidosis is rare but can occur in 
a plastic surgeon’s practice.
The surgical pathologist may miss amyloid deposits, 
especially if the deposits are very discrete. When diagnosis 
of amyloidosis is done, it is mandatory to rule out a 
concomitant breast cancer or a systemic amyloidosis. In 
Figure 7, we present a flow chart to guide clinicians in the 
diagnostic pathway.
Figure 7: Flow chart for diagnosis of amyloidosis
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Moreover, recognition and appropriate classification of 
amyloid deposits in biopsy specimens is mandatory, 
independently of whether amyloidosis is local, organ-
limited or generalized to help diagnose concomitant 
conditions (i.e. B-cell or plasma cell proliferation for AL, 
chronic inflammatory diseases for AA as previously 
explained).[1] Breast amyloidosis treatment options 
include conservative excision of the nodules or, in rare 
and diffuse cases such as the one presented, mastectomy 
can be considered.
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